Patent 9493462 was granted and assigned to Boehringer Ingelheim on November, 2016 by the United States Patent and Trademark Office.
The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament.